---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-004800"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-01-18T23:59:59+00:00"
generated_at: "2026-06-06T21:51:38.869300+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Esperion Therapeutics discloses preliminary cash balance of $82M as of Dec 29, 2023

## Summary
- Preliminary cash, cash equivalents and short-term investments total $82.0M as of December 29, 2023.
- Amount is preliminary and subject to completion of financial closing procedures.
- Full quarterly and year-end financial results for December 31, 2023 not yet released.
- Ernst & Young has not audited or reviewed this preliminary data.

## SEC filing metadata
- accession: 0001104659-24-004800
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-01-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465924004800/0001104659-24-004800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465924004800/tm243338d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-004800
- JSON: https://secwatch.observer/filing/0001104659-24-004800.json
- Plain text: https://secwatch.observer/filing/0001104659-24-004800.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.